LivaNova PLC (LIVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LivaNova PLC (LIVN) has a cash flow conversion efficiency ratio of 0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.22 Million) by net assets ($1.21 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LivaNova PLC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
LivaNova PLC - Cash Flow Conversion Efficiency Trend (1992–2025)
This chart illustrates how LivaNova PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
LivaNova PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LivaNova PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grand Canyon Education Inc
NASDAQ:LOPE
|
0.127x |
|
flatexDEGIRO AG
XETRA:FTK
|
1.644x |
|
LG Display
KO:034220
|
0.078x |
|
Iskenderun Demir ve Celik AS
IS:ISDMR
|
0.152x |
|
Unilever Indonesia Tbk
JK:UNVR
|
-0.115x |
|
Merdeka Copper Gold PT
JK:MDKA
|
0.019x |
|
Antar Chile
SN:ANTARCHILE
|
0.005x |
|
Torex Gold Resources Inc
TO:TXG
|
0.083x |
Annual Cash Flow Conversion Efficiency for LivaNova PLC (1992–2025)
The table below shows the annual cash flow conversion efficiency of LivaNova PLC from 1992 to 2025. For the full company profile with market capitalisation and key ratios, see how much is LivaNova PLC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.20 Billion | $254.30 Million | 0.212x | +52.86% |
| 2024-12-31 | $1.32 Billion | $183.04 Million | 0.139x | +136.44% |
| 2023-12-31 | $1.28 Billion | $74.91 Million | 0.059x | +1.30% |
| 2022-12-31 | $1.21 Billion | $69.90 Million | 0.058x | -26.92% |
| 2021-12-31 | $1.29 Billion | $102.54 Million | 0.079x | +210.66% |
| 2020-12-31 | $1.11 Billion | $-79.40 Million | -0.072x | -8.67% |
| 2019-12-31 | $1.38 Billion | $-91.14 Million | -0.066x | -182.20% |
| 2018-12-31 | $1.50 Billion | $120.50 Million | 0.080x | +59.33% |
| 2017-12-31 | $1.82 Billion | $91.30 Million | 0.050x | -4.82% |
| 2016-12-31 | $1.71 Billion | $90.20 Million | 0.053x | +20.14% |
| 2015-12-31 | $1.81 Billion | $79.68 Million | 0.044x | -78.97% |
| 2014-12-31 | $259.10 Million | $54.20 Million | 0.209x | 0.00% |
| 2013-12-31 | $259.10 Million | $54.20 Million | 0.209x | -39.26% |
| 2012-12-31 | $229.57 Million | $79.05 Million | 0.344x | -15.79% |
| 2011-12-31 | $183.47 Million | $75.03 Million | 0.409x | +43.86% |
| 2010-12-31 | $175.45 Million | $49.87 Million | 0.284x | +14.84% |
| 2009-12-31 | $173.27 Million | $42.89 Million | 0.248x | -0.61% |
| 2008-12-31 | $98.74 Million | $24.59 Million | 0.249x | -73.03% |
| 2007-12-31 | $15.65 Million | $14.46 Million | 0.923x | -33.88% |
| 2006-12-31 | $-14.81 Million | $-20.69 Million | 1.397x | +109.12% |
| 2005-12-31 | $4.63 Million | $-70.88 Million | -15.308x | -29052.47% |
| 2004-12-31 | $75.60 Million | $-3.97 Million | -0.053x | -200.75% |
| 2003-12-31 | $68.98 Million | $3.60 Million | 0.052x | +175.46% |
| 2002-12-31 | $67.42 Million | $1.28 Million | 0.019x | +103.55% |
| 2001-12-31 | $43.02 Million | $-22.95 Million | -0.533x | -77.18% |
| 1999-12-31 | $27.15 Million | $-8.18 Million | -0.301x | +31.59% |
| 1998-12-31 | $33.40 Million | $-14.70 Million | -0.440x | -9.73% |
| 1997-12-31 | $36.90 Million | $-14.80 Million | -0.401x | -63.11% |
| 1996-12-31 | $48.80 Million | $-12.00 Million | -0.246x | +96.16% |
| 1995-12-31 | $1.50 Million | $-9.60 Million | -6.400x | -600.95% |
| 1994-12-31 | $6.90 Million | $-6.30 Million | -0.913x | -201.63% |
| 1993-12-31 | $18.50 Million | $-5.60 Million | -0.303x | -51.98% |
| 1992-12-31 | $24.10 Million | $-4.80 Million | -0.199x | -- |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. … Read more